Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis

Meriggioli, 2009, Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity, Lancet Neurol., 8, 475, 10.1016/S1474-4422(09)70063-8

Miller, 2000, A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations, Mult. Scler., 6, 267, 10.1177/135245850000600408

Yamasaki, 2016, Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica, Mult. Scler., 22, 1337, 10.1177/1352458515617248

Nozaki, 2013, Neurosarcoidosis, Curr. Treat. Options Neurol., 15, 492, 10.1007/s11940-013-0242-9

Arsura, 1985, High-dose intravenous methylprednisolone in myasthenia gravis, Arch. Neurol., 42, 1149, 10.1001/archneur.1985.04060110031011

Komiyama, 2000, Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis, J. Neurol. Neurosurg. Psychiatry, 68, 214, 10.1136/jnnp.68.2.214

Lindberg, 1998, Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study, Acta Neurol. Scand., 97, 370, 10.1111/j.1600-0404.1998.tb05968.x

Kanai, 2019, Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis, J. Neurol. Sci., 396, 8, 10.1016/j.jns.2018.10.018

Kupersmith, 2005, Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment, Br. J. Ophthalmol., 89, 1330, 10.1136/bjo.2004.063404

Benatar, 2016, Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial, Muscle Nerve, 53, 363, 10.1002/mus.24769

Porter, 2005, Ocular myasthenia gravis, Curr. Treat. Options Neurol., 7, 79, 10.1007/s11940-005-0009-z

Wolfe, 1999, Myasthenia gravis activities of daily living profile, Neurology, 52, 1487, 10.1212/WNL.52.7.1487

Murai, 2014, Clinical features and treatment status of adult myasthenia gravis in Japan, Clin. Exp. Neuroimmunol., 5, 84, 10.1111/cen3.12091

Kerty, 2014, EFNS/ENS guidelines for the treatment of ocular myasthenia, Eur. J. Neurol., 21, 687, 10.1111/ene.12359

Kaminski, 2000, Treatment of ocular myasthenia: steroids only when compelled, Arch. Neurol., 57, 752, 10.1001/archneur.57.5.752

Sussman, 2015, Myasthenia gravis: Association of British Neurologists' management guidelines, Pract. Neurol., 15, 199, 10.1136/practneurol-2015-001126

Murai, 2015, Japanese clinical guidelines for myasthenia gravis: putting into practice, Clin. Exp. Neuroimmunol., 6, 21, 10.1111/cen3.12180

Fukumoto, 2015, Three cases of myasthenia gravis treated effectively with high-dose intravenous methylprednisolone pulse therapy for the extraocular muscle paralysis, Neuro-Ophthalmol. Japan, 32, 285

Soltys, 2008, Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?, Ann. N. Y. Acad. Sci., 1132, 220, 10.1196/annals.1405.037